POTOMAC — Durvalumab plus BCG Induction and Maintenance in High-Risk BCG-Naive Non-Muscle Invasive Bladder Cancer

Phase 3 · 2025 · Bladder Cancer

Design

Randomized trial of durvalumab plus BCG induction and maintenance versus BCG induction and maintenance alone.

Population

High-risk, BCG-naive non-muscle invasive bladder cancer (NMIBC).

Primary Endpoint

disease-free survival (DFS)

Key Result

Adding durvalumab to BCG induction and maintenance produced a statistically significant improvement in disease-free survival versus BCG alone in high-risk BCG-naive NMIBC; mature overall survival and patient-reported outcomes continue to be tracked.

Guideline Impact

High-risk BCG-naive non-muscle invasive bladder cancer